Clinical trial • Not applicable • Musculoskeletal|Other
epinephrine, lidocaine hydrochloride for Distal radius fracture
Not applicable trial of epinephrine, lidocaine hydrochloride for Distal radius fracture.
Overview
- Trial Therapeutic Area
- Musculoskeletal|Other
- Trial Disease
- Distal radius fracture
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 18-06-2024
- First CTIS Authorization Date
- 12-09-2024
Trial design
Randomised, two arms: 1) ultrasound-guided brachial plexus nerve block using lidokain-adrenalin (epinephrine and lidocaine hydrochloride) solution, perineural administration (product: lidokain-adrenalin sad, injektionsvæske, opløsning). dose details not specified in protocol documents beyond smpc information (product records list dose unit mg/kg and max total dose 7 mg/kg). 2) haematoma block (standard care).-controlled Not applicable trial across 12 sites in Denmark.
- Randomised
- Yes
- Comparator
- Two arms: 1) Ultrasound-guided brachial plexus nerve block using Lidokain-adrenalin (epinephrine and lidocaine hydrochloride) solution, perineural administration (product: Lidokain-adrenalin SAD, injektionsvæske, opløsning). Dose details not specified in protocol documents beyond SmPC information (product records list dose unit mg/kg and max total dose 7 mg/kg). 2) Haematoma block (standard care).
- Target Sample Size
- 1716
- Trial Duration For Participant
- 90
Eligibility
Recruits 1716 Vulnerable population not selected. Only adults (age ≥ 18 years) are eligible. Informed consent is required ("Lack of informed consent" is an exclusion criterion). No assent process or other vulnerable-population consent arrangements are described..
- Vulnerable Population
- Vulnerable population not selected. Only adults (age ≥ 18 years) are eligible. Informed consent is required ("Lack of informed consent" is an exclusion criterion). No assent process or other vulnerable-population consent arrangements are described.
Inclusion criteria
- {"criterion_text":"- Adults (age ≥ 18 years) with a distal radius fracture in need of closed reduction"}
Exclusion criteria
- {"criterion_text":"- Patients who would never qualify for surgery according to local guidelines"}
- {"criterion_text":"- Lack of informed consent"}
- {"criterion_text":"- No Danish Central Person Register (CPR) number"}
- {"criterion_text":"- Allergies to the trial medication"}
- {"criterion_text":"- Distal radius fracture initially deemed to require surgery regardless of the outcome of the closed reduction"}
- {"criterion_text":"- Open fracture (fracture-related wound requiring sutures), other fractures on the same extremity (NOT including distal ulna fracture(s)) or bilateral distal radius fractures both requiring closed reduction."}
- {"criterion_text":"- Concomitant medical or surgical condition taking priority over the closed reduction of the distal radius fracture."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Cumulative proportion of patients with distal radius fracture surgery 90 days after closed reduction","definition_or_measurement_approach":"Measured as the cumulative proportion of participants undergoing distal radius fracture surgery within 90 days after the closed reduction procedure."}
Secondary endpoints
- {"endpoint_text":"- Composite outcome of treatment related complications: loco-regional neurological complications from affected arm, local anaesthetic systemic toxicity, soft tissue injuries related to the closed reduction procedure, infection at the site of needle puncture, vessel puncture requiring subsequent treatment, pneumothorax, allergic reaction, new bone or joint injury after the closed reduction and/or pulmonary embolism witin 90 days after closed reducti","definition_or_measurement_approach":"Composite of specified treatment-related complications occurring within 90 days after closed reduction (as listed)."}
- {"endpoint_text":"- Patient Rated Wrist Evaluation (PRWE) 90 days after closed reduction","definition_or_measurement_approach":"PRWE score assessed at 90 days after closed reduction."}
- {"endpoint_text":"- Maximum pain score (Numerical Rating Scale (NRS) 0-10) in the affected wrist during closed reduction(s)","definition_or_measurement_approach":"Maximum NRS (0-10) pain score recorded in the affected wrist during closed reduction procedure(s)."}
- {"endpoint_text":"- Proportion of patients with unacceptable radiographic fracture position immediately after closed reduction, according to AAOS guidelines","definition_or_measurement_approach":"Proportion determined by assessing immediate post-reduction radiographs against AAOS guidelines criteria for unacceptable fracture position."}
Recruitment
- Planned Sample Size
- 1716
- Recruitment Window Months
- 29
- Consent Approach
- Informed consent is required from each participant; lack of informed consent is an exclusion. Only adults (≥18 years) are eligible. Subject information and informed consent forms are available in Danish and English (multiple document versions present). No assent process described.
Geography
- Total Number Of Sites
- 12
- Total Number Of Participants
- 1716
Denmark
- Earliest CTIS Part Ii Submission Date
- 02-08-2024
- Latest Decision Or Authorization Date
- 03-11-2025
- Processing Time Days
- 458
- Number Of Sites
- 12
- Number Of Participants
- 1716
Sites
- Site Name
- Region Midtjylland
- Department Name
- Department of Operation and Intensive Care
- Contact Person Name
- Jeppe Henriksen
- Contact Person Email
- jephen@rm.dk
- Site Name
- Slagelse Hospital
- Department Name
- Department of Anaesthesiology and Intensive Care
- Contact Person Name
- Jesper Kent Nielsen
- Contact Person Email
- jken@regionsjaelland.dk
- Site Name
- Holbaek Sygehus
- Department Name
- Department of Emergency Medicine
- Contact Person Name
- Jógvan Olivar Matras
- Contact Person Email
- jogm@regionsjaelland.dk
- Site Name
- Hvidovre Hospital
- Department Name
- Department of Anaesthesiology and Intensive Care
- Contact Person Name
- Rune Sort
- Contact Person Email
- rune.sort.01@regionh.dk
- Site Name
- Region Midtjylland
- Department Name
- Department of Emergency Medicine
- Contact Person Name
- Malik Kalmriz
- Contact Person Email
- alik@aarhus.rm.dk
- Site Name
- Region Hovedstaden
- Department Name
- Dept. of Orthopedic Surgery
- Contact Person Name
- Pelle Baggesgaard Petersen
- Contact Person Email
- Pelle.baggesaard.petersen.02@regionh.dk
- Site Name
- Lillebaelt Hospital
- Department Name
- Department of Anaesthesiology
- Contact Person Name
- Morten Rune Blichfeldt-Eckhardt
- Contact Person Email
- mr.be@rsyd.dk
- Site Name
- Region Midtjylland
- Department Name
- Department of Orthopaedic
- Contact Person Name
- Per Hviid Guntofte
- Contact Person Email
- pergun@rm.dk
- Site Name
- Zealand University Hospital
- Department Name
- Department of Orthopaedic Surgery
- Contact Person Name
- Danny Yu
- Contact Person Email
- dy@regionsjaelland.dk
- Site Name
- Odense University Hospital
- Department Name
- Department of Orthopaedic Surgery
- Contact Person Name
- Joakim Jensen
- Contact Person Email
- Joakim.jensen@rsyd.dk
- Site Name
- Copenhagen University Hospital
- Department Name
- Department of Anaesthesiology and Intensive Care
- Contact Person Name
- Troels Haxholdt Lunn
- Contact Person Email
- lunn@dadlnet.dk
- Site Name
- Hillerod Hospital
- Department Name
- Department of Anaesthesiology and Intensive Care
- Contact Person Name
- Anders Kehlet Nørskov
- Contact Person Email
- anders.kehlet.noerskov@regionh.dk
Sponsor
Primary sponsor
- Full Name
- Region Hovedstaden
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"sponsorDuties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- Lidokain-adrenalin SAD, injektionsvæske, opløsning
- Active Substance
- epinephrine, lidocaine hydrochloride
- Modality
- Small molecule
- Routes Of Administration
- Perineural use
- Route
- Perineural
- Authorisation Status
- Marketing-authorised in Denmark (marketingAuthNumber 16318)
- Maximum Dose
- 7 mg/kg (max total dose)
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- Tafamidis (free acid) for Transthyretin amyloidosis
- Dexamethasone sodium phosphate for Total hip arthroplasty
- Sufentanil for Traumatic limb injury|Pain in limb
- ROPIVACAINE HYDROCHLORIDE for Lumbar arthrodesis|Spinal arthrodesis
- Betamethasone dipropionate; Betamethasone sodium phosphate for Degenerative meniscal lesion